A market pullback is coming -- sometime. Here's why to buy AbbVie, Allergan, and Celgene stocks when it happens.
A slate of collaborations and a potential game-changing pain medicine have fueled a big run-up in this company's share price.
Growth opportunities for Bristol-Myers Squibb make this drug stock a bargain.
Tesaro's stock is surging higher ahead of the potential approval of a game-changing drug for ovarian cancer.
Johnson & Johnson has a good dividend. But AbbVie, Bristol-Myers Squibb, and Pfizer lay claim to much better yields.
AbbVie beats out Bristol-Myers Squibb, Johnson & Johnson, Novo Nordisk, Roche, and Teva to claim the prize of best big pharma dividend stock.
Is a spin-off of one of its business segments in the cards for Johnson & Johnson this year? Stranger things have happened before.
Will AbbVie face a rocky road in the new year because of these significant risks?
It was a banner year for companies developing drugs associated with compounds found in marijuana.
AstraZeneca's shares continued their downward spiral last month, falling by more than 8%.